BCM
HUMA icon

Bridgeway Capital Management’s Humacyte HUMA Stock Holding History

Bridgeway Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125K Sell
160,000
-50,000
-24% -$46.3K ﹤0.01% 1125
2026
Q1 		$127K Hold
210,000
– – ﹤0.01% 1102
2025
Q4 		$202K Buy
210,000
+35,000
+20% +$49.6K ﹤0.01% 1017
2025
Q3 		$305K Hold
175,000
– – 0.01% 924
2025
Q2 		$366K Buy
+175,000
New +$336K 0.01% 827

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bridgeway Capital Management's HUMA Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Humacyte (HUMA) stake by 24% in Q2 2026, selling an estimated $46.3K and leaving 160,000 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #1125.

Bridgeway Capital Management first reported a position in HUMA in Q2 2025 and has held it in 5 quarters since. The position peaked at $366K in Q2 2025. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Bridgeway Capital Management held 160,000 shares of Humacyte worth $125K as of Q2 2026.
  • Bridgeway Capital Management sold 50,000 Humacyte shares in Q2 2026, an estimated $46.3K.
  • Humacyte made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1125 holding.
  • Bridgeway Capital Management first reported a position in Humacyte in Q2 2025 and has held it in 5 quarters since.
  • Bridgeway Capital Management's Humacyte position peaked at $366K in Q2 2025.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.